retatrutide weight loss studies Will Reta Rewrite Obesity? Retatrutide (“reta”) is an experimental

A 2.6% reduction in hip bone mineral density and a 2.1% reduction at the lumbar spine in 52 weeks (Hansen et al., 2024), combined with up to 10.9% lean mass loss over 72 weeks (Look et al., 2025), means that patients on GLP-1 therapy need a comprehensive musculoskeletal protection plan from day one

Consuming fewer calories than these minimums for extended periods can lead to nutrient deficiencies, muscle loss, metabolic slowdown, and other health complications

The patient has established cardiovascular disease with a documented history of at least one of the following: A) Previous myocardial infarction (MI) B) Previous stroke C) Symptomatic peripheral arterial disease (PAD), evidenced by one of the following: Intermittent claudication with an ankle-brachial index (ABI) less than 0.85 at rest Peripheral arterial revascularization procedure Amputation due to atherosclerotic disease D) Prior revascularization, such as coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or angioplasty, and

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

While generally safe, individuals should consult their healthcare provider before starting IM injections, especially if they have pre-existing health conditions or allergies